We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




WHO Review Recommends Artemisinin Suppositories for Emergency Malaria Treatment

By HospiMedica staff writers
Posted on 09 Apr 2008
A recent study concluded that suppositories containing a member of the artemisinin family of drugs were effective for early treatment for severe malaria in remote settings where injectable anti-malarial therapy may not be feasible. More...


Artemisinin (a sesquiterpene lactone) is isolated from the shrub Artemisia annua long used in traditional Chinese medicine for the treatment of malaria. Not all shrubs of this species contain artemisinin, which apparently it is only produced when the plant is subjected to certain conditions. It can be synthesized from artemisinic acid. Artesunate is a semi-synthetic derivative of artemisinin that is water-soluble and may be given by injection.

In the study sponsored by the World Health Organization (Geneva, Switzerland) individual patient data from 1167 patients in 15 clinical trials of rectal artemisinin derivative therapy (artesunate, artemisinin, and artemether) were pooled in order to compare the rapidity of clearance of Plasmodium falciparum parasites from the blood and the incidence of reported adverse events with each treatment. A parasite reduction of >90% at 24 hours was defined as parasitological success.

Results reported in the March 28, 2008, online edition of the open access journal BMC Infectious Diseases revealed that artemisinin and artesunate suppositories rapidly eliminated parasites and appeared to be safe. There was less data on artemether and dihydroartemisinin suppositories. A single higher dose of rectal artesunate treatment was five times more likely to achieve >90% parasite reductions at 24 hours than were multiple lower doses of rectal artesunate, or a single lower dose administration of rectal artemether. The more rapid parasite clearance of single high-dose regimens suggested that achieving immediate high drug concentrations might be the optimal strategy.

The authors concluded, "Early effective treatment with artemisinin-based suppositories has potential as a lifesaving intervention, particularly at the periphery of the health-care system, where suppositories might be administered early in lieu of parenteral treatment in remote communities by relatively untrained personnel. Combined with accurate diagnosis and artemisinin-based combination therapy, rectal artemisinins have been effectively used to reduce malaria incidence and mortality in Asia, an approach which holds great promise for malaria control elsewhere.”


Related Links:
World Health Organization

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.